News | January 01, 2025
Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Merck has also decided to end the favezelimab clinical development program
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
The product will be marketed by Dr. Reddy's
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Subscribe To Our Newsletter & Stay Updated
